Presenters, including Nobel Laureate in Medicine, to discuss innovative treatments for neurodegeneration
Company to feature lead therapeutic's statistically significant benefits, p < 0.007, for severe Alzheimer's disease (AD) patients
NEW YORK, Dec. 6, 2023 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that its President and Chief Scientific Officer, Daniel Alkon, M.D., will join more than 30 leading neuroscientists and academics as a speaker at IABS Forum-2023, "New Concepts for the Treatment of Neurodegenerative Disorders." The distinguished scientific forum, to be held on December 7-8, 2023 in Irvine, CA, is co-sponsored by the University of Southern California School of Pharmacy and the International Association of Biomedical Sciences (IABS).
The forum's keynote address, entitled "Towards a Cell Biology of Alzheimer's Disease," will be delivered by Dr. Thomas Südhof, Nobel Laureate in Physiology or Medicine 2013. Dr. Südhof is known for his groundbreaking research on the mechanisms underlying synaptic transmission, which plays a vital role in learning, memory, and various neurological processes.
AD is also the topic of Dr. Alkon's presentation. He will speak about the latest clinical results for Bryostatin-1, which, as previously disclosed, met the secondary efficacy endpoints in the Phase 2 trial with statistical significance. In the Phase 2 trial, no significant cognitive decline was observed throughout the 10-month study, with Bryostatin-1 demonstrating safe, significant, and persistent benefits at least 16 weeks beyond the final dosing. A research article detailing the results was published earlier this year in the Journal of Alzheimer's Disease.
"I am honored to accept the invitation to speak at IABS Forum-2023, in the company of many of the world's greatest minds in neuroscience," said Dr. Alkon. "Renowned institutions, publishers, and symposiums continue to recognize the benefits of our novel therapy, developed to restore synaptic loss, and its potential for advanced stage Alzheimer's patients."
About Synaptogenix
Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases. Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Preclinical studies have also demonstrated Bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders such as multiple sclerosis, stroke, and traumatic brain injury. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome. Bryostatin-1 has already undergone testing in more than 1,500 people in cancer studies, thus creating a large safety data base that will further inform clinical trial designs.
包括諾貝爾醫學獎得主在內的主持人將討論神經變性的創新療法
公司將介紹先導療法對嚴重阿爾茨海默病(AD)患者的統計學顯著益處,p < 0.007
紐約,2023 年 12 月 6 日 /PRNewswire/ — 開發神經退行性疾病療法的新興生物製藥公司 Synaptogenix, Inc.(納斯達克股票代碼:SNPX)(“Synaptogenix” 或 “公司”)今天宣佈,其總裁兼首席科學官丹尼爾·阿爾康醫學博士將與30多位領先的神經科學家和學者一起在IABS上發表演講論壇2023,“神經退行性疾病治療的新概念”。傑出科學論壇將於2023年12月7日至8日在加利福尼亞州爾灣舉行,由南加州大學藥學院和國際生物醫學協會(IABS)共同贊助。
論壇的主題演講題爲 “邁向阿爾茨海默氏病的細胞生物學”,將由2013年諾貝爾生理學或醫學獎得主托馬斯·蘇德霍夫博士主講。蘇德霍夫博士以其對突觸傳播機制的開創性研究而聞名,突觸傳遞在學習、記憶和各種神經系統過程中起着至關重要的作用。
AD 也是阿爾康博士演講的主題。他將介紹Bryostatin-1的最新臨床結果,正如先前披露的那樣,該結果在2期試驗中達到了次要療效終點,具有統計學意義。在2期試驗中,在爲期10個月的研究中,未觀察到明顯的認知能力下降,Bryostatin-1在最終給藥後至少16周顯示出安全、顯著和持續的益處。今年早些時候,在《阿爾茨海默氏病雜誌》上發表了一篇詳細介紹研究結果的研究文章。
阿爾康博士說:“我很榮幸接受邀請,在2023年IABS論壇上發表演講,屆時有許多世界上神經科學領域的傑出人才。”“知名機構、出版商和研討會繼續認識到我們爲恢復突觸損失而開發的新療法的益處,及其對晚期阿爾茨海默氏症患者的潛力。”
關於 Synaptogenix
Synaptogenix是一家處於臨床階段的生物製藥公司,歷來致力於開發治療神經退行性疾病的新療法。Synaptogenix已對其治療阿爾茨海默病的主要候選藥物Bryostatin-1進行了臨床和臨床前研究。臨床前研究還表明,Bryostatin對罕見疾病Fragile X綜合徵以及多發性硬化、中風和創傷性腦損傷等其他神經退行性疾病具有再生作用機制。美國食品藥品監督管理局已授予Synaptogenix孤兒藥稱號,用於治療脆性X綜合徵的Bryostatin-1。Bryostatin-1已經在癌症研究中對1,500多人進行了測試,從而創建了一個龐大的安全數據庫,可以進一步爲臨床試驗設計提供信息。